Kamada jumps on $50m source plasma deal
Kamada (Nasdaq: KMDA; TASE: KMDA) said it signed a three-year normal source plasma supply agreement with a biopharmaceutical company. The deal is expected to generate about $50 million in revenue over three years, with initial commercial sales recorded in Q4 2026. Kamada noted its Texas collection centers are ramping to support the supply.
How this was made
The 30-second read
Why it matters
The agreement validates Kamada’s U.S. collection investment and provides a measurable revenue contribution over three years, with initial commercial sales expected in Q4 2026.
Market read
Deal size and timing improve revenue visibility and can influence valuation assumptions around collection ramp and contracted demand.
What to watch
The article does not specify pricing per liter, expected volumes at ramp, contract take-or-pay terms, or whether the customer can switch suppliers, which are key drivers of realized profitability.
Background
Kamada operates FDA-approved plasma collection centers in Houston and San Antonio, designed for normal source plasma collection with planned capacity of about 50,000 liters per year per center at full capacity.
Ticker impact
Kamada announced a three-year normal source plasma supply agreement expected to generate about $50 million in revenue, with initial sales in Q4 2026.
Near-term upside bias from the disclosed $50 million deal size, with follow-through likely dependent on collection ramp progress and customer demand through 2026.
The article discloses deal economics ($50m over three years) and timing (initial sales in Q4 2026), which can re-rate revenue visibility, though it does not provide margin, pricing, or customer concentration details.
Market effects
Reinforces demand visibility for plasma-derived therapy supply chains and highlights the value of vertically integrated collection capacity in the specialty plasma sector.
Strengthens the investment narrative around U.S. plasma collection operations, specifically Texas capacity ramp-up.
Signals ongoing global outsourcing and supply contracting for plasma-derived therapies, potentially affecting competitive dynamics among plasma collectors.
Counterpoint
A $50 million three-year revenue figure may be modest relative to broader financial expectations, so the stock reaction could fade without margin and volume details.
Key entities
- companyKamada
Israeli biopharmaceutical company supplying normal source plasma from Texas collection centers under a three-year agreement.
